Key facts
- It has raised $80K; the latest was Early Stage VC in Apr 2026.
- Notable investors include National Institutes of Health, University of Virginia, Blackbird Laboratories, Cville BioHub, Portal Innovations.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Vasarya Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Vasarya Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vasarya Therapeutics
Opearator of a biotechnology company intended to discover and translate novel therapeutics by leveraging the power of mechanobiology. The company specializes in developing a more efficacious, safer drug for tissue remodeling disorders by leveraging opportunities in mechanobiology.
- Sector
- Healthcare
- HQ
- Charlottesville, VA, United States
- Founded
- 2022
- Employees
- 4
- Website
- vasarya.com/
- Ownership
- Privately Held (backing)
Vasarya Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vasarya Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vasarya Therapeutics in its N-PORT filings yet. We sweep new filings monthly.